Aurobindo Pharma Ltd.
🇮🇳India
- Country
- 🇮🇳India
- Ownership
- Public
- Established
- 1986-01-01
- Employees
- 10K
- Market Cap
- $10.8B
- Website
- http://www.aurobindo.com
Pharmacodynamic Bioequivalence Study of Albuterol Sulfate Inhalation Aerosol, 0.09 mg Albuterol Base/ Inhalation
Phase 3
Withdrawn
- Conditions
- Bronchial Asthma
- Interventions
- First Posted Date
- 2022-03-23
- Last Posted Date
- 2022-05-20
- Lead Sponsor
- Aurobindo Pharma Ltd
- Registration Number
- NCT05292976
- Locations
- 🇺🇸
Investigational site #1, San Jose, California, United States
Clinical Endpoint Bioequivalence Study of Adapalene Gel 0.1%
Phase 3
Withdrawn
- Conditions
- Acne Vulgaris
- Interventions
- First Posted Date
- 2020-04-01
- Last Posted Date
- 2020-06-26
- Lead Sponsor
- Aurobindo Pharma Ltd
- Registration Number
- NCT04329403
Clinical Pharmacodynamic Bioequivalence Study of Beclomethasone Dipropionate 40 mcg INH
Phase 3
Completed
- Conditions
- Bronchial Asthma
- Interventions
- Drug: Test ProductDrug: PlaceboDrug: Reference Product
- First Posted Date
- 2019-08-09
- Last Posted Date
- 2020-11-13
- Lead Sponsor
- Aurobindo Pharma Ltd
- Target Recruit Count
- 1550
- Registration Number
- NCT04051710
- Locations
- 🇮🇳
Maharashtra Medical Foundation Joshi Hospital, Pune, Maharashtra, India
Steady State Global Bioequivalence Study of Amphotericin B Liposome for Injection 50 mg/ Vial in Fed Condition
Phase 1
Completed
- Conditions
- Visceral Leishmaniasis
- Interventions
- First Posted Date
- 2018-08-17
- Last Posted Date
- 2019-08-26
- Lead Sponsor
- Aurobindo Pharma Ltd
- Target Recruit Count
- 140
- Registration Number
- NCT03636659
- Locations
- 🇮🇳
Kala-Azar medical Research Centre, Muzaffarpur, Bihar, India
🇮🇳Rajendra Memorial Research Institute of Medical Sciences, Patna, Bihar, India
🇧🇩International Centre for Diarrhoeal Disease Research b, Dhaka, Bangladesh
© Copyright 2025. All Rights Reserved by MedPath